Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2022-02-14 4:23 pm Sale | 13G | Cue Biopharma Inc. CUE | Corriente Advisors LLC | 0 0.000% | -1,915,219 (Position Closed) | View |
2022-02-14 4:10 pm Sale | 13G | TFF PHARMACEUTICALS INC NE TFFP | Corriente Advisors LLC | 0 0.000% | -1,350,000 (Position Closed) | View |
2022-02-14 4:04 pm Sale | 13G | Cardiff Oncology Inc. CRDF | Corriente Advisors LLC | 0 0.000% | -2,000,000 (Position Closed) | View |
2021-02-16 06:33 am Purchase | 13G | TFF PHARMACEUTICALS INC NE TFFP | Corriente Advisors LLC | 1,350,000 6.070% | 1,350,000 (New Position) | View |
2021-02-16 06:28 am Purchase | 13G | Cue Biopharma Inc. CUE | Corriente Advisors LLC | 1,915,219 6.330% | 1,915,219 (New Position) | View |
2021-02-16 06:26 am Sale | 13G | ASTRIA THERAPEUTICS INC ATXS | Corriente Advisors LLC | 0 0.000% | -804,584 (Position Closed) | View |
2021-02-16 06:23 am Sale | 13G | BOWFLEX INC.INC. BFXXQ | Corriente Advisors LLC | 0 0.000% | -1,813,822 (Position Closed) | View |
2021-02-16 06:18 am Purchase | 13G | Cardiff Oncology Inc. CRDF | Corriente Advisors LLC | 2,000,000 5.660% | 2,000,000 (New Position) | View |
2020-02-10 4:07 pm Purchase | 13G | ASTRIA THERAPEUTICS INC ATXS | Corriente Advisors LLC | 804,584 6.710% | 201,455 (+33.40%) | View |
2020-01-23 12:39 pm Purchase | 13G | BOWFLEX INC.INC. BFXXQ | Corriente Advisors LLC | 1,813,822 6.100% | 1,813,822 (New Position) | View |